Ablacon, Inc. Announces $30 Million Series B Financing and Expansion of Scientific Advisory Board

Jan 07, 2021•over 4 years ago

Amount Raised

$30 Million

Round Type

series b

Menlo Park

Description

Ablacon, Inc., an Ajax Health-backed company, announced the close of a $30 million Series B financing, with Zeus Health joining as new lead investor. Ablacon also announced the addition of Dr. David Haines, Professor of Cardiovascular Medicine at Oakland University William Beaumont School of Medicine and Director of the Heart Rhythm Center at Beaumont Health, Royal Oak, MI, to the company's scientific advisory board (SAB).

Company Information

Company

Ablacon

Location

Menlo Park, California, United States

About

Ablacon, Inc. has offices in Menlo Park, California, Munich, Germany and Denver, Colorado, and has developed an advanced mapping system to guide the treatment of atrial fibrillation, the most frequent cardiac arrhythmia. The company's system uses advanced algorithms and machine learning to precisely localize and characterize the sources of AF and to guide targeted therapy by visualizing the Electrographic Flow within the cardiac chambers. The company's technology obtained CE Mark in 2018 and is currently being used in Europe.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Ablacon, Inc. Announces $30 Million Series B Financing and Expansion of Scientific Advisory Board

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information